創新醫療(002173.SZ)：擬與許科帝合資設立“腦機接口”項目公司
格隆匯 1 月 19日丨創新醫療(002173.SZ)公佈，公司擬與許科帝合資設立“腦機接口”項目公司(具體名稱以市場監督管理部門核准名稱為準，“平台公司”)。平台公司註冊資本為5000萬元，公司以自有資金人民幣2000萬元出資，佔比40%。
為了強化項目人員責任心，控制公司投資項目風險，基於收益共享和風險共擔的原則，公司要求馬三光和李小龍作為“腦機接口”合作項目的具體負責人員，以自有資金對合作項目進行跟投。馬三光現任公司董事長助理，李小龍現任公司第五屆監事會監事，此次交易構成關聯交易，但不構成《上市公司重大資產重組管理辦法》規定的重大資產重組情況，無需提交公司股東大會審議。
許科帝：39歲，現任浙江大學求是高等研究院教授，兼職受聘於浙江大學生物醫學工程系，中國生物醫學工程學會康復工程分會委員，中國康復輔助器具協會康復工程專業委員會委員。2010年7月畢業於浙江大學生物醫學工程與儀器科學學院，獲工學博士學位，師從鄭筱祥教授從事心血管和神經系統定量生理的研究。2012年9月加入浙江大學求是高等研究院，主要研究方向圍繞雙向閉環植入式腦機接口的開發與應用，研究成果包括基於光、電刺激的感知覺反饋技術、雙向閉環神經調控方法研究及器件開發，基於植入式腦機接口的運動功能控制與重建技術，參與完成國內首例運動皮層植入式腦機接口的臨牀轉化工作。相關工作獲得國家自然科學基金、國防軍工項目、浙江省科技廳公益項目和教育部博士點基金等多項基金的資助，參與了973項目、863計劃、十三五重大專項、國家自然基金重點項目和國家自然基金儀器專項在內的多項重大科研項目。學習和工作期間累計發表SCI和EI收入論文60餘篇，其中第一作者或通訊作者論文35篇。作為團隊主要成員獲得教育部2016年度十大科技進展和中國人工智能學會吳文俊人工智能進步獎一等獎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
